INOVIO Form 4 — Sumner Michael John (June 30, 2022)

Summary

Michael John Sumner, Chief Medical Officer of INOVIO PHARMACEUTICALS, INC. [ INO ], reports awards dated 06/30/2022: 160,000 Common Stock Options with a $ 1.73 exercise price expiring 06/30/2032, and 105,000 Restricted Stock Units. The options vest 40,000 shares at a time, the first on June 30, 2022 and the rest each June 30 through 2025; the units vest 35,000 shares on June 30 of 2023, 2024 and 2025. Table I lists no common stock transactions. The form is signed /s/ Michael John Sumner, 07/06/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Sumner Michael John (Last) (First) (Middle) 660 W. GERMANTOWN PIKE SUITE 110 (Street) PLYMOUTH MEETING PA 19462 (City) (State) (Zip) | Sumner Michael John | (Last) | (First) | (Middle) | 660 W. GERMANTOWN PIKE | SUITE 110 | PLYMOUTH MEETING | PA | 19462 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [ INO ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Medical Officer | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | Chief Medical Officer
3. Date of Earliest Transaction
 (Month/Day/Year) 06/30/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Common Stock Options | $ 1.73 | 06/30/2022 | A | 160,000 | (1) | 06/30/2032 | Common Stock | 160,000 | $ 0 | 160,000 | D
Restricted Stock Unit | (2) | 06/30/2022 | A | 105,000 | (2) | (2) | Common Stock | 105,000 | $ 0 (2) | 105,000 | D
Explanation of Responses:
1. The vesting schedule for the 160,000 options is as follows: 40,000 shares vested on June 30, 2022; 40,000 shares will vest on June 30, 2023; 40,000 shares will vest on June 30, 2024; 40,000 shares will vest on June 30, 2025.
2. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 105,000 restricted stock units is as follows: 35,000 shares will vest on June 30, 2023; 35,000 shares will vest on June 30, 2024; 35,000 shares will vest on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
Remarks:
/s/ Michael John Sumner | 07/06/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_INO_4_filed2022-07-06_0001055726-22-000044.xml

Size

17,123 bytes

SHA-256

cf197bdd6f8df5ead24568d2ba72e33521d2abbff8eb493eba558eaf2a5bda0d

Our copy

SEC_INO_4_filed2022-07-06_0001055726-22-000044.xml

Original

www.sec.gov